Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2010-02-11
2011-11-22
Jarrell, Noble (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S219000, C514S220000, C540S474000, C540S554000, C540S555000, C540S562000
Reexamination Certificate
active
08063032
ABSTRACT:
Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
REFERENCES:
patent: 2479152 (1949-08-01), Brooker
patent: 3642778 (1972-02-01), Helsley et al.
patent: 4252816 (1981-02-01), Saari et al.
patent: 4490463 (1984-12-01), Gilbert
patent: 5013748 (1991-05-01), Radtke et al.
patent: 5845025 (1998-12-01), Garito et al.
patent: 5852191 (1998-12-01), Karandikar et al.
patent: 5856384 (1999-01-01), Garito et al.
patent: 6410550 (2002-06-01), Coe et al.
patent: 6413956 (2002-07-01), Albaugh et al.
patent: 6451520 (2002-09-01), Odenwalder et al.
patent: 6515122 (2003-02-01), Lang et al.
patent: 6605610 (2003-08-01), Coe et al.
patent: 7056942 (2006-06-01), Hildesheim et al.
patent: 2002/0002161 (2002-01-01), Ennis et al.
patent: 2005/0026910 (2005-02-01), Roush et al.
patent: 2005/0096342 (2005-05-01), Zefirov et al.
patent: 2005/0239767 (2005-10-01), Chan et al.
patent: 2006/0090269 (2006-05-01), Lagrange
patent: 2006/0217370 (2006-09-01), Burstein et al.
patent: 2007/0117834 (2007-05-01), Hung
patent: 2007/0225316 (2007-09-01), Bachurin et al.
patent: 2008/0234310 (2008-09-01), Bachurin et al.
patent: 2009/0042873 (2009-02-01), Dubois et al.
patent: 2009/0163545 (2009-06-01), Goldfarb
patent: 2009/0186879 (2009-07-01), Aso et al.
patent: 2009/0221627 (2009-09-01), Aksinenko et al.
patent: 2009/0239854 (2009-09-01), Hung et al.
patent: 2009/0270412 (2009-10-01), Hung et al.
patent: 2010/0022580 (2010-01-01), Hung et al.
patent: 2010/0056790 (2010-03-01), Aksinenko et al.
patent: 2010/0099667 (2010-04-01), Hung et al.
patent: 2010/0099700 (2010-04-01), Hung
patent: 2010/0120792 (2010-05-01), Ivashchenko et al.
patent: 2010/0152108 (2010-06-01), Hung et al.
patent: 2010/0152163 (2010-06-01), Hung et al.
patent: 2010/0152225 (2010-06-01), Hung
patent: 2010/0178277 (2010-07-01), Hung et al.
patent: 2010/0216814 (2010-08-01), Hung et al.
patent: 2010/0252823 (2010-10-01), Kambe et al.
patent: 2010/0273778 (2010-10-01), Cowart et al.
patent: 2010/0278811 (2010-11-01), Wrasidlo et al.
patent: 2010/0286188 (2010-11-01), Bachurin et al.
patent: 2010/0298287 (2010-11-01), Aso et al.
patent: 2011/0065694 (2011-03-01), Chytil et al.
patent: 2231560 (1974-01-01), None
patent: 1990355 (2008-03-01), None
patent: 618889 (1949-03-01), None
patent: 04149180 (1992-05-01), None
patent: 2001022129 (2001-01-01), None
patent: 2005033185 (2005-02-01), None
patent: 2009203311 (2009-09-01), None
patent: WO 96/29331 (1996-09-01), None
patent: WO 98/43649 (1998-10-01), None
patent: WO 01/98263 (2001-12-01), None
patent: WO 2005/040144 (2005-05-01), None
patent: WO 2006/084833 (2006-08-01), None
patent: WO 2007/065820 (2007-06-01), None
patent: WO 2007/117180 (2007-10-01), None
patent: WO 2008073231 (2008-06-01), None
patent: WO 2009005771 (2009-01-01), None
patent: WO 2009017836 (2009-02-01), None
patent: WO 2009039420 (2009-03-01), None
patent: WO 2009111540 (2009-09-01), None
patent: WO 2009135091 (2009-11-01), None
patent: WO 2010/062065 (2010-06-01), None
patent: WO 2010/093425 (2010-08-01), None
patent: PCT/US2010/048199 (2010-09-01), None
patent: PCT/US2010/048201 (2010-09-01), None
patent: WO 2010127177 (2010-11-01), None
patent: WO 2010144571 (2010-12-01), None
patent: WO 2011/014695 (2011-02-01), None
patent: WO 2011/019417 (2011-02-01), None
patent: WO 2011031816 (2011-03-01), None
patent: WO 2011031818 (2011-03-01), None
Agundez et al., 2008, “Nonsynonymous Polymorphisms of Histamine-Metabolising Enzymes in Patients with Parkinson's Disease,” Neuromol. Med., 10, 10-16.
Alcalde et al., 1992, “Heterocyclic Betaines, Novel Ethyleneimidazolium Benzimidazolate Inner Salts. Synthesis, Characterization, and Transformation into 2-Vinyl-1H-benzimidazoles,” Chem. Lett., 2357-60.
Alcalde et al., 1996, “Synthesis of Dipolar Ethyleneimidazolium Benzimidazolate Inner Salts and Their Transformation to 2-Vinylbenzimidazoles Through a Type of β-Elimination Reaction,” Heterocycles, 43(3), 567-80.
Anichtchik et al., 2000, “Modulation of Histamine H3 Receptors in the Brain of 6-Hydroxydopamine-Lesioned Rats,” Eur. J. Neuroscience, 12, 3823-32.
Anichtchik et al., 2001, “Distribution and Modulation of Histamine H3 Receptors in Basal Ganglia and Frontal Cortex of Healthy Controls and Patients with Parkinson's Disease,” Neurobio. Disease, 8, 707-16.
Barbier et al., 2004, “Acute Wake-Promoting Actions of JNJ-5207852, a Novel, Diamine-Based H3 Antagonist,” Brit. J. Pharm., 143, 649-61.
Bertaccini et al., 1995, “An Update on Histamine H3 Receptors and Gastrointestinal Functions,” Digestive Disease & Sciences, 40(9), 2052-63.
Breunig et al., 2007, “Histamine Excites Neurons in the Human Submucous Plexus Through Activation of H1, H2, H3 and H4 Receptors,” J. Physiol., 583(2), 731-42.
Brown et al., 2001, “The Physiology of Brain Histamine,” Prog. Neurobio., 63, 637-72.
Laurence L. Brunton et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics 629-51 (11th ed. 2006).
Chavez et al., 2005, “Histamine (H3) Receptors Modulate the Excitatory Amino Acid Receptor Response of the Vestibular Afferents,” Brain Research, 1064(1-2), 1-9.
Cherkaoui et al., 1991, “Heterocyclization of the 2-Aminoalkyl (and aryl) Benzimidazoles Under Phase Transfer Catalysis Conditions,” Bulletin de la Societe Chimique de France, 255-59.
Clapham et al., 1994, “Thioperamide, the Selective Histamine H3 Receptor Antagonist, Attenuates Stimulant-Induced Locomotor Activity in the Mouse,” Eur. J. Pharm., 259, 107-14.
Claramunt et al., 1998, “Conformational Analysis of Heterocyclic Analogues of 5,6,11,12-Tetrahydrodibenzo[a,e]cyclooctene: 6,7,14,15-Tetrahydrobisbenzimidazo[1,2-a:1′,2′-e][1,5]diazocine and 6,7,13,14-Tetrahydrobispyrido[1,2-a:1′,2′-e]diazocinediium Dibromide,” Tetrahedron, 54, 9569-80.
Day et al., 2007, “Differential Effects of Ciproxifan and Nicotine on impulsivity and Attention Measures in the 5-Choice Serial Reaction Time Test,” Biochem. Pharm., 73, 1123-34.
El Abbassi et al., 1990, “Synthesis of Pyrozolo[2′,3′:1,7][1,4]diazepino[4,5-a]benzimidazoles and of 1-Alkyl-2-[(5-methyl-3-pyrazolyl)methyl]benzimidazoles,” Bulletin de la Societe Chimique de France, (1), 117-28.
Elguero et al., 1976, “Synthesis, Spectra, and Crystal Structure of 6,7,14,15-Tetrahydrobisbenzimidazo[1,2-a:1′,2′-e][1,5]diazocine,” J.C.S. Perkin Trans I, (3), 312-15.
Ennis et al., 2003, “2,3,4,5-Tetrahydro-and 2,3,4,5,11,11 a-Hexahydro-1H-[1,4]diazepino[1,7-a]indoles: New Templates for 5HT2C Agonists,” Bioorg. Med. Chem. Lett., 13, 2369-72.
Esbenshade et al., 2004, “Pharmacological and Behavioral Properties of A-349821, a Selective and Potent Human Histamine H3 Receptor Antagonist,” Biochem. Pharm., 68, 933-45.
Esbenshade et al., 2006, “Histamine H3 Receptor Antagonists: Preclinical Promise for Treating Obesity and Cognitive Disorders,” Molecular Interventions, 6(2), 77-88.
Esbenshade et al., 2008, “The Histamine H3 Receptor: An Attractive Target for the Treatment of Cognitive Disorders,” Brit. J. Pharm., 154(6), 1166-81.
Fox et al., 2002, “Effects of Histamine H3 Receptor Ligands GT-2331 and Ciproxifan in a Repeated Acquisition Avoidance Response in the Spontaneously Hypertensive Rat Pup,” Behavioural Brain Research, 131, 151-61.
Fox et al., 2003, “Two Novel and Selective Nonimidazo
Chytil Milan
Fang Qun Kevin
Spear Kerry L.
Jarrell Noble
Sunovion Pharmaceuticals Inc.
LandOfFree
Histamine H3 inverse agonists and antagonists and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histamine H3 inverse agonists and antagonists and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histamine H3 inverse agonists and antagonists and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254766